antiviral

(redirected from Anti-viral)
Also found in: Dictionary, Thesaurus.

antiviral

 [an″te-, an″ti-vi´ral]
1. effective against viruses.
2. an agent effective against viruses.

an·ti·vi·ral

(an'tē-vī'răl),
Opposing a virus; interfering with its replication; weakening or halting its action (for example, zidovudine, acyclovir).

antiviral

/an·ti·vi·ral/ (-vi´ral) destroying viruses or suppressing their replication, or an agent that so acts.

antiviral

(ăn′tē-vī′rəl, ăn′tī-)
adj.
1. Destroying or inhibiting the growth and reproduction of viruses.
2. Computers
a. Of or relating to antivirus software.
b. Eliminating or inhibiting the effectiveness of viruses.
n.
An antiviral drug.

antiviral

destructive to viruses.

antiviral

adjective Referring to an agent or mechanism that counters viral effects or infection.
 
noun An agent that inhibits or prevents viral infection or manages its effects; an antiviral agent.

antiviral

adjective Referring to an agent or mechanism that counters viral effects or infection noun Antiviral agent, see there.

an·ti·vi·ral

(an'tē-vī'răl)
Opposing a virus; interfering with its replication; weakening or abolishing its action.

antiviral

Acting against viruses.

Antiviral

Refers to a drug that can destroy viruses and help treat illnesses caused by them.
Mentioned in: Monkeypox

antiviral

agent opposing effect of a virus; some antiviral agents interact with some local anaesthetics (see Table 1)
Table 1: Principal drug interactions of local anaesthetic agents and other medications
Local anaesthetic agent Proprietary name Principal drug interactionsEffect of interaction
Lidocaine
Xylocaine
Antiarrhythmic agents
Antibacterial agents
Antipsychotics
Antivirals
Beta-blockers
Diuretics
Dolasetron
Ulcer-healing drugs
Increased myocardial depression
Increased risk of ventricular arrhythmias if lidocaine is given with quinpristin/dalfopristin
Increased risk of ventricular arrhythmias if lidocaine is given with any drug that prolongs the QT interval of the cardiac cycle
Plasma concentration of lidocaine increased by amprenavir, atazanavir and lopinavir
Increased myocardial depression
Increased risk of lidocaine toxicity when given with propranolol
The action of lidocaine is antagonized by the hypokalaemia caused by acetazolamide, loop diuretics or thiazide and related diuretics (i.e. a greater dose of lidocaine would be required to achieve anaesthesia)
Increased risk of ventricular arrhythmia if lidocaine is given with dolasetron
Plasma concentration of lidocaine increased when given with cimetidine; risk of lidocaine toxicity increased with cimetidine
Bupivacaine
Marcain
Levo-bupivacaine
Chirocaine
Beta-blockersIncreased risk of bupivacaine toxicity when given with propranolol
Increased risk of myocardial depression if given with other antiarrhythmic agents
Prilocaine
Citanest
Antiarrhythmic agents
Antibacterial agents
Increased risk of myocardial depression if given with antiarrhythmic agents
Increased risk of methaemoglobinaemia if given with sulphonamide antibacterial agents
Ropivacaine
Naropin
AntidepressantsMetabolism of ropivacaine is inhibited by fluvoxamine, thereby enhancing the risk of ropivacaine toxicity
Mepivacaine
Scandonest
Drug not listed in the British National Formulary

antiviral (anˈ·tē·vīˑ·rl),

n a substance that combats viral infection.

an·ti·vi·ral

(an'tē-vī'răl)
Opposing a virus; interfering with its replication; weakening or halting its action (e.g., zidovudine, acyclovir).

antiviral

1. effective against viruses.
2. an agent effective against viruses.

antiviral drugs
may be useful in early stages of some virus infections or to prevent recurrences or reactivation in chronic infections. Most drugs exert their effects only during certain stages of viral replication and many are relatively toxic for the host when used systemically. In general, chemotherapy of virus infections in animals is uncommon with limited applications, mainly in topical treatment of ophthalmic infections. Examples are idoxuridine, vidarabine, amantadine hydrochloride, acyclovir, ribavirin.
References in periodicals archive ?
This grant recognizes the potential of RNAi therapeutics as a new class of anti-viral drugs for the treatment and prevention of highly virulent strains of flu and the promising pre-clinical data emerging from our flu program," said John Maraganore, Ph.
The team places peptides on the molecule that tell T cells that tumors are actually virus-infected cells, so anti-viral T cells now target and kill what they believe to be a virus-infected cell.
The unique advantage of ONCONASE(R) relative to other conventional anti-viral agents lies in its effectiveness in treating mutant forms of viruses.
Anti-Viral 2003 consists of several homeopathic ingredients specifically designed to provoke an increased immune response by the body in a manner similar to interferon (a naturally occurring protein which helps the body to counter infection).
This is Arrow's first partnership with a major biopharmaceutical company and we are delighted to be working with Triangle in this area since they are a leading anti-viral clinical development company.
Kleenex Anti-Viral tissue sets a new standard in the ongoing battle against cold and flu viruses," said Dr.
Nasdaq: ALNY), a leading RNAi therapeutics company, announced today that the National Institute of Allergy and Infectious Diseases (NIAID), a component of the National Institutes of Health (NIH), has awarded the company a contract to advance the development of a broad spectrum RNAi anti-viral therapeutic against hemorrhagic fever virus, including the Ebola virus.
The specific phospholipids targeted by Tarvacin Anti-Viral come from the human host and are incorporated into the envelop the virus acquires as it leaves the host's cells to propagate and spread the viral infection.
com/reports/c16346 ) has announced the addition of 2004 Anti-viral Therapy Collection CD to their offering.
Perdue said, "We know from surveillance studies and from hospital clinical studies that resistance to the two primary anti-viral drugs, the Tamiflu and Amantadine drugs, have already occurred, The H5N1 strain of the virus does not sleep and always constitutes a danger.
Their expertise in specific viral infections will support Peregrine's development of Tarvacin(TM) Anti-Viral, an investigational monoclonal antibody therapy with unique anti-viral properties.
Unfortunately, only a fraction of patients respond to the current anti-viral therapy and, perhaps more disturbingly, patients thought to have cleared the virus are frequently found to harbor detectable levels of viral message within a new extrahepatic cellular compartment, the peripheral blood leukocytes.